The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

Article, Other literature type English OPEN
Jardine, Meg J.; Mahaffey, Kenneth W.; Neal, Bruce; Agarwal, Rajiv; Bakris, George L.; Brenner, Barry M.; Bull, Scott; Cannon, Christopher P.; Charytan, David M.; de Zeeuw, Dick; Edwards, Robert; Greene, Tom; Heerspink, Hiddo J. L.; Levin, Adeera; Pollock, Carol; Wheeler, David C.; Xie, John; Zhang, Hong; Zinman, Bernard; Desai, Mehul; Perkovic, Vlado;
  • Publisher: S. Karger AG
  • Related identifiers: pmc: PMC5804835, doi: 10.1159/000484633
  • Subject: Chronic kidney disease | IRBESARTAN | Original Report: Patient-Oriented, Translational Research | CARDIOVASCULAR OUTCOMES | GLOMERULAR-FILTRATION-RATE | PROGRESSION | KIDNEY-DISEASE | Renal outcomes | ALBUMINURIA | ATRIAL-NATRIURETIC-PEPTIDE | Canagliflozin | LOSARTAN | COLLABORATIVE METAANALYSIS | GFR DECLINE | Diabetic nephropathy

Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to i... View more
Share - Bookmark